|Day Low/High||0.74 / 0.76|
|52 Wk Low/High||0.51 / 5.46|
Company to Host Quarterly Conference Call at 8:30 am EDT Tomorrow
Too many investors have a fundamental misunderstanding about the significance of orphan drug designation. I should say, insignificance, because the FDA delineation, on its own, means very little.
Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow
Catalyst Pharmaceuticals (CPRX) stock is sinking on heavy trading volume on Wednesday after the company announced that it received a 'Refusal to File' letter from the FDA.
Levi & Korsinsky announces it has commenced an investigation of Catalyst Pharmaceuticals, Inc.
The FDA deems the approval application for the Catalyst drug Firdapse to be 'not sufficiently complete' and requests additional information.
Investors in Catalyst Pharmaceuticals Inc saw new options begin trading this week, for the September 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Company to host quarterly conference call at 8:30am ET tomorrow
The most recent short interest data was recently released by the NASDAQ for the 09/30/2015 settlement date, and Catalyst Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 8.73 "days to cover" versus the median component at 5.50. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
Doctors and patients say something must be done to stop Catalyst Pharmaceuticals from emulating the high-priced drug strategies of Valeant and Turing Pharma.